Salute e Benessere

Medical Equipment Maintenance Market size worth $ 94.13 Billion, Globally, by…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=315383 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=315383 Browse in-depth TOCon" Medical Equipment Maintenance Market " 202 - Pages 126 – Tables 37 – Figures Medical Equipment Maintenance Market: Transformative Trends and Key Players Unveiled in Upcoming Global Study In the ever-evolving landscape of healthcare, the demand for advanced medical...
PR Newswire
07/11/2023

Calliditas to present at upcoming investor conferences

For further information, please contact:Åsa Hillsten, Head of IR & Sustainability, CalliditasTel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com For further information, please contact : Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email:asa.hillsten@calliditas.com The information was sent for publication, through the agency of the contact persons set out above, onNovember 7, 2023, at16:00 p.m. CET. The following files are available...
PR Newswire
07/11/2023

Leukapheresis Market size worth $ 100647.54 Million, Globally, by 2028 at 6.08%…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=144881 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=144881 Browse in-depth TOCon" Leukapheresis Market " 202 - Pages 126 – Tables 37 – Figures Groundbreaking Insights Unveiled: Leukapheresis Market Set for Unprecedented Growth In a groundbreaking revelation, the Leukapheresis Market, a cornerstone of medical innovation, has been identified as a...
PR Newswire
07/11/2023

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 7 November 2023— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and...
Nasdaq GlobeNewswire
07/11/2023

Remote Patient Monitoring (RPM) Market Worth $41.7 Billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77155492 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77155492 Browse in-depth TOC on "Remote Patient Monitoring (RPM) Market" 157 - Tables 34 - Figures 205 - Pages Remote Patient Monitoring (RPM) Market Scope: Software and services is expected to register the highest CAGR during the forecast period Based on the product, the...
PR Newswire
07/11/2023

Immunovia successfully completes discovery phase of next-generation test…

"We are excited to announce significant progress in the development of our next-generation test to detect early-stage pancreatic cancer. In the past three months, we have significantly restructured and streamlined our operations, which is paying off with the rapid and cost-efficient development of our next-generation test," Jeff Borcherding, Immunovia CEO. "We are excited to announce significant progress in the development of our next-generation test to detect early-stage…
PR Newswire
07/11/2023

Portable Dental Chair Market to Reach $147.3 Million, Globally, by 2032 at 4.3%…

Request Sample of the Report on Portable Dental Chair Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/214544 Request Sample of the Report on Portable Dental Chair Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/214544 Prime determinants of growth Rise in prevalence of dental infections such as dental caries and periodontal diseases, increase in adoption of portable dental chairs, and rise in advancements in portable dental chair...
PR Newswire
07/11/2023

Discovery Life Sciences Announces New CEO

Mr. Herrema joins Discovery following a successful career at Thermo Fisher Scientific, where he served as senior vice president and president of the global life sciences company's $8 billion+ laboratory supply distribution business. He previously led its biosciences, analytical instruments, scientific instruments, and environmental instruments businesses. Mr. Herrema began his career at General Electric. He serves on multiple non-profit boards focused on land conservation and community…
PR Newswire
07/11/2023

The Arab International Women's Forum and Pfizer launch 'DEI by Design' report…

The report provides recommendations to lift up women in health. Among many solutions, the report highlights the importance of addressing acute health and mental health challenges for women in conflict-ridden countries and include their voices in decision-making processes to humanise medical provisions for refugees; investing in a robust homegrown research culture in the region; advocating for enhanced collaboration between health authorities, hospitals, and universities to establish organised…
PR Newswire
07/11/2023

Philips program developing AI-powered ultrasound to expand access to maternal…

Total investment from the Bill & Melinda Gates Foundation reaches USD 60 million, accelerating expansion of new AI-guided ultrasound capabilities on Philips Lumify Handheld UltrasoundInnovation helps address worldwide shortage of healthcare workers by putting diagnostic tool previously reserved for expert technicians in the hands of midwives Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has...
Nasdaq GlobeNewswire
07/11/2023

Turn Biotechnologies First to Deliver mRNA into the Dermis Using Proprietary…

Since the skin is the body's natural layer of protection, delivering mRNA therapeutics within a lipid nanoparticle delivery system to a specific dermal target is a significant achievement. Researchers have delivered mRNA-based therapies to the lungs, spleen and liver, but no one has previously been able to target the dermal layer of the skin – the body's largest organ. Since the skin is the body's natural layer of protection, delivering mRNA therapeutics within a lipid nanoparticle delivery...
PR Newswire
07/11/2023

Alvotech to Present at the Jefferies 2023 London Healthcare Conference

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference taking place in London on November 14-16, 2023. Alvotech's presentation is scheduled on Wednesday, November 15, 2023 at 1:00 pm GMT. A webcast of the presentation will also be available and can be accessed in the Investors Section of Alvotech's website underNews and...
Nasdaq GlobeNewswire
07/11/2023

ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing…

In accordance with Section 802.01C of the NYSE Listed Company Manual, the Company has a cure period of six months from receipt of the notice to regain compliance with the continued listing minimum price criteria. The notice has no immediate impact on the listing of the Company's common shares, which will remain listed and traded on the NYSE during this period, subject to the Company's compliance with the other continued listing requirements.The Company can regain compliance if on the last...
Nasdaq GlobeNewswire
07/11/2023

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent…

~ Announced FDA clearance of Investigational New Drug (IND) application for AMT-260 in refractory mesial temporal lobe epilepsy ~ ~ On track to provide clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington's disease later in the fourth quarter of 2023 ~~ uniQure and CSL win 2023 Prix Galien USA award for HEMGENIX ®~~ Announced strategic reorganization to focus on advancing multiple clinical-stage programs and expect to deliver $180 million...
Nasdaq GlobeNewswire
07/11/2023

TÜV Rheinland Awards Product Carbon Footprint Certification to the Hisense Laser…

By analyzing the carbon emissions at the various stages of the product life cycle, Hisense can more intuitively identify the high emission "Hotspots" of the overall life cycle, and examine the impact of each stage on the environment from the product perspective, to prepare product optimization plans more effectively while evaluating energy management, life cycle analysis, raw materials and supply chain management. By analyzing the carbon emissions at the various stages of the product…
PR Newswire
07/11/2023

iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates

- Initiation of GALAXIES H&N-202, a Phase 2 platform study assessing TIGIT:PD-1 doublet and other novel IO combinations, including a CD96 triplet in HNSCC - Completed enrollment of monotherapy dose escalation arm in TIG-007 Phase 2 trial in multiple myeloma - Completed enrollment of first dose cohort in Phase 1 trial of EOS-984 - Cash balance and investment balance of $644.9 million as of September 30, 2023 expected to provide runway through 2026 across a number of impactful...
Nasdaq GlobeNewswire
07/11/2023

ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides…

3Q 2023 ZYNLONTA ®1net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductionsOperating expenses decreased 23% 2year-over-yeardue to portfolio prioritization and operational efficiencies; Expected cash runway into mid-2025Prioritized pipeline progressing with initial data readouts from LOTIS-7 and studies of ADCT-601 targeting AXL and ADCT-901 targeting KAAG1 expected in 1H...
Nasdaq GlobeNewswire
07/11/2023

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

AC Immune to Present at the Jefferies 2023 London Healthcare ConferenceLausanne, Switzerland, November 7, 2023– AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2023 London Healthcare Conference, taking place in-person in London on November 14-16, 2023.The fireside chat...
Nasdaq GlobeNewswire
07/11/2023

Global HLA Typing Market Size is to grow from USD 1.1 billion in 2023 to USD 2.1…

Several factors, such as an increase in the demand for diagnostic products, greater collaboration between public and private sectors for extensive HLA research, a rise in the prevalence of infectious diseases, and an increase in transplant procedures, are fueling the market growth. HLA typing employs DNA-based molecular diagnostics to identify HLA class I and II antigens. These innovative DNA technologies provide more accurate and robust results by identifying differences in HLA genes…
PR Newswire
07/11/2023

Diamyd Medical partners with DiaUnion to recruit participants for Type 1…

DiaPrecise is the first precision prevention trial with Diamyd®, and is conducted under the ASSET program (AI for the Sustainable Prevention of Autoimmunity in Society, www.asset.healthcare) funded by the Swedish Innovation Agency VINNOVA. DiaUnion is a consortium coordinated by the Medicon Valley Alliance involving also the Steno Diabetes Center Copenhagen and Lund University, Malmö, establishing a screening program to identify individuals positive for diabetes autoantibodies, and there at high…
PR Newswire
07/11/2023

Registration for the 7th IFPA Conference 2024 now open

Key Dates: Key Dates: The IFPA Conference is a unique platform where delegates can explore psoriatic disease from various perspectives by networking with patients and industry representatives in attendance. It provides a crucial opportunity for sharing the latest clinical research findings, promoting collaborative efforts, and advancing the understanding of all aspects of psoriatic disease. In the words of April Armstrong , the conference president, and Chair of the SEC, "Together,...
PR Newswire
07/11/2023

Update relating to LEQEMBI® from Eisai's investor presentation of their…

BioArctic's complete interim report for the third quarter 2023 will be published on November 8 at 08:00 CET. BioArctic's complete interim report for the third quarter 2023 will be published onNovember 8at08:00 CET. This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, onNovember 7, 2023, at09:15 a.m. CET...
PR Newswire
07/11/2023

Huma signs partnership with Merck KGaA, Darmstadt, Germany to support cancer…

Set for initial launch in 2024, the preliminary direct-to-patient solution will support urothelial carcinoma patients in the UK. Regulated platform will drive improved treatment adherence Utilising Huma's disease-agnostic Software as a Medical Device (SaMD) technology platform, the first of its kind to achieve both EU MDR Class IIb regulation and FDA Class 2 510(k) clearance, the collaboration between Huma and Merck KGaA, Darmstadt,Germanyaspires to (with local...
PR Newswire
07/11/2023

Enzymatica AB - Interim report Q3/2023: Research results that reshape the…

"The positive research results presented during the quarter contribute to us trusting our financial goals for 2026.. Sales in our own markets Sweden, UK and Iceland are doing very well, with a market share in Sweden that is one of the highest for several years. We are discussing constructive ways forward together with our current partners since sales outside of our own markets have been lower than expected. I am very pleased to see how the recent research findings have sparked an interest…
PR Newswire
07/11/2023
Altri  Comunicati